IL-9: From Birth to Breath – at FOCIS 2024
The International Cytokine and Interferon Society Sponsored Symposium at FOCIS 2024: IL-9: From Birth to Breath – Although IL-9 was first described in the late 1980s, its regulation and functions are still not well defined. Initially thought to be a mast cell and T cell growth factor, IL-9 was subsequently reclassified as a type 2 cytokine after extensive data implicated it in atopic dermatitis, food allergy, and allergic asthma. More recently, work has implicated IL-9 as a major player in autoimmunity and antitumor immunity. New endotype-based classification systems have led many leaders in the field to speculate that “IL-9-high” endotypes have clinically relevant translational applications to precision medicine treatments of allergic, autoimmune, and malignant conditions. This has led to a renaissance of papers defining beneficial and pathogenic functions of IL-9 in disease. This symposium will focus on recent developments in IL-9 biology including a role for IL-9 in pregnancy and the function of IL-9 in allergic disease.
